CN Patent

CN103209704A — 有机化合物

Assigned to Intra Cellular Therapies Inc · Expires 2013-07-17 · 13y expired

What this patent protects

本发明涉及如本文所述的游离的固体药学可接受的盐和/或基本上纯的形式的特定取代的杂环稠合γ-咔啉类、其前体药物、其药物组合物和在治疗涉及5-HT 2A 受体、5-羟色胺转运蛋白(SERT)和/或涉及多巴胺D 2 受体信号传导途径的途径的疾病中的使用方法。

USPTO Abstract

本发明涉及如本文所述的游离的固体药学可接受的盐和/或基本上纯的形式的特定取代的杂环稠合γ-咔啉类、其前体药物、其药物组合物和在治疗涉及5-HT 2A 受体、5-羟色胺转运蛋白(SERT)和/或涉及多巴胺D 2 受体信号传导途径的途径的疾病中的使用方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN103209704A
Jurisdiction
CN
Classification
—
Expires
2013-07-17
Drug substance claim
No
Drug product claim
No
Assignee
Intra Cellular Therapies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.